drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous anti-CD19 CAR T cells)
drug_description
Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy in which a patient’s T cells are engineered ex vivo to express an anti-CD19 CAR; upon infusion, the cells deplete CD19+ B cells and plasmablasts to suppress autoreactive B-cell activity and autoantibody production in SLE/lupus nephritis.
nci_thesaurus_concept_id
C175534
nci_thesaurus_preferred_term
Rapcabtagene Autoleucel
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, rapcabtagene autoleucel is directed to and induces selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered ex vivo to express an anti‑CD19 chimeric antigen receptor. After infusion, CAR engagement with CD19 on B cells and plasmablasts activates the T cells to kill CD19+ B‑lineage cells, leading to profound B‑cell depletion and suppression of autoreactive B‑cell activity and autoantibody production in SLE/lupus nephritis.
drug_name
rapcabtagene autoleucel
nct_id_drug_ref
NCT06581198